Abraham Scaria

The Bill & Melinda Gates Foundation was formed in 1997 as the William H. Gates Foundation. In 1999, the foundation was renamed the Bill & Melinda Gates Foundation. The Bill & Melinda Gates Foundation Trust was created in January 2000 through the merger of the Gates Learning Foundation, which worked to expand access to technology through public libraries and the William H. Gates Foundation, which focused on improving global health. The foundation participates in preventive approaches and collaborative endeavors with government, philanthropic and not-for-profit partners. Priority is given to grants that leverage additional support and serve as a catalyst for long-term, systemic change. The foundation also provides funds to promote greater equity in global health, education and public libraries. Through their partnerships in communities across the US, the Bill & Melinda Gates Foundation is committed to raising the high school graduation rate and helping all students, regardless of race or family income. The foundation is headquartered in Seattle, Washington.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA.

Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Scioderm, Inc. engages in the development of innovative therapies for areas of high unmet need, including orphan products. The company was founded by Robert Ryan and Robert John Coull in 2012 and is headquartered in Durham, NC.

Intersouth Partners (Intersouth Partners) is a venture capital firm founded in 1985 by Dennis Dougherty and Roy Rodwell. The firm is headquartered in Durham, North Carolina.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Part of Intersouth Partners, Intersouth Associates VI LLC provides investment services. The company is based in Durham, NC and was founded in 2003.

BioFlorida, Inc. is an organization that represents the life science industry in Florida. The private company is based in Florida and represents over 6,700 establishments and research organizations in the biopharmaceutical, medical technology, and bioagriculture sectors, providing employment to 94,000 Floridians. The American company's initiatives aim to create a favorable business environment for the development of innovative products and technologies that enhance people's lives and bring economic benefits to the state. Nancy K. Bryan has been the CEO of the company since 2013.

Apposite Capital LLP (Apposite Capital) is a private equity arm of Mizuho Financial Group, Inc. founded in 2016 by David Porter. The firm is headquartered in London, United Kingdom.

Simon-Kucher & Partners GmbH provides strategy, marketing and pricing services. It offers consulting services in the areas of setting and managing prices, strategic development, product and market strategy, marketing leadership, and sales execution. The firm has offices in Amsterdam, Bonn, Boston, Brussels, Cologne, Frankfurt, London, Luxembourg, Barcelona, Madrid, Milan, Moscow, Munich, New York, Paris, San Francisco, Tokyo, Vienna, Warsaw, Beijing, Singapore, Sydney and Zurich. The company was founded by Hermann Simon, Eckhard Kucher and Karl-Heinz Sebastian in 1985 and is headquartered in Bonn, Germany.

Florida High Tech Corridor Council, Inc. provides regional economic development services for universities. The private company is based in Heathrow, FL. The CEO of the company is Paul Sohl.

Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA.

Public Health Foundation offers health assistance solutions. It specializes in public health quality improvement, public health workforce development, public health resources and tools and strengthening the quality and performance of public health practice. The company was founded in 1970 and is headquartered in Washington, DC.

Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA.

Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

The Gainesville Area Chamber of Commerce operates as a chamber of commerce.

NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom.

Artizan Biosciences, Inc. engages in the provision of healthcare services. It develops curative treatments for inflammatory diseases. The company was founded by Richard A. Flavell, Noah W. Palm and Marcel R. de Zoete and is headquartered in New Haven, CT.

Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom.